RT Journal Article
SR Electronic
T1 Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.11.22273754
DO 10.1101/2022.04.11.22273754
A1 García-Grimshaw, Miguel
A1 Galnares-Olalde, Javier Andrés
A1 Bello-Chavolla, Omar Yaxmehen
A1 Michel-Chávez, Anaclara
A1 Cadena-Fernández, Arturo
A1 Briseño-Godínez, María Eugenia
A1 Antonio-Villa, Neftali Eduardo
A1 Nuñez, Isaac
A1 Gutiérrez-Romero, Alonso
A1 Hernández-Vanegas, Laura
A1 del Mar Saniger-Alba, María
A1 Carrillo-Mezo, Roger
A1 Ceballos-Liceaga, Santa Elizabeth
A1 Carbajal-Sandoval, Guillermo
A1 Flores-Silva, Fernando Daniel
A1 Díaz-Ortega, José Luis
A1 López-Gatell, Hugo
A1 Cortes-Alcalá, Ricardo
A1 Pérez-Padilla, José Rogelio
A1 Chiquete, Erwin
A1 Reyes-Terán, Gustavo
A1 Arauz, Antonio
A1 Valdés-Ferrer, Sergio Iván
YR 2022
UL http://medrxiv.org/content/early/2022/04/12/2022.04.11.22273754.abstract
AB Background Guillain-Barré syndrome (GBS) as an adverse event following immunization (AEFI) against SARS-CoV-2 has been linked to a few (ChAdOx1 nCov-19 and Ad26.COV2-S), but not all vaccines, including mRNA-based ones. Epidemiological information on GBS among recipients of other SARS-CoV-2-directed vaccines among Latinx/Hispanic recipients is scarce.Methods We report GBS incidence per million administered doses from a nationwide Mexican retrospective registry of adult (≥18 years) recipients of 81,842,426 doses of seven vaccines against SARS-CoV-2 immunized between December 24, 2020, and October 29, 2021. Cases were collected through a passive epidemiological surveillance system and defined as events occurring within 42 days from immunization. Vaccines were analyzed individually and by vector as either mRNA-based (mRNA-1273 and BNT162b2), adenovirus-vectored (ChAdOx1 nCov-19, rAd26-rAd5, Ad5-nCoV, and Ad26.COV2-S), or inactivated whole-virion-vectored (CoronaVac).Findings We identified 97 patients (52 [53.6%] males; median age 44 years (interquartile range 33–60), for an overall observed incidence of 1.19/1,000,000 doses (95% confidence interval [CI] 0.97–1.45), higher among Ad26.COV2-S (3.86/1,000,000 doses, 95% CI 1.50–9.93) and BNT162b2 (1.92/1,00,000 doses, 95% CI 1.36–2.71) recipients. The overall interval from vaccination-to-GBS symptoms onset was 10 days (interquartile range 3–17). Preceding diarrhea (≤ 4 weeks) was reported in 21.6%, and four (4.1%) more had mild COVID-19. Only 18 patients were tested for Campylobacter jejuni infection; 16 (88.9%) were positive. Electrophysiological examinations were performed in 76 (78.4%) patients (axonal in 46 [60.5%] and demyelinating in 25 [32.8%]); variants were similar between platforms. On initial evaluation, 91.8% had a GBS disability score ≥ 3. Seventy-five (77.3%) patients received intravenous immunoglobulin, seven (7.2%) plasma exchanges, and 15 (15.5%) were treated conservatively. There were 10 (10.3%) deaths, and 79.1% of survivors were unable to walk independently at discharge.Interpretation In our population, GBS was an infrequent AEFI, observed in less than 1.2/1,000,000 administered doses of vaccines against SARS-CoV-2. Observed incidences were higher among Ad26.COV2.S and BNT162b2 recipients individually and for mRNA-vectored vaccines as a group.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Consejo Nacional de Ciencia y Tecnología (CONACyT), México: grants 289788 and A1-S-18342 (both to SIV-F)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (ID: NER-3903-21-23-1) Ethics and Research Committees who waived the need for signed informed consent due to its observational nature and usage of an anonymized databaseI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript